Hydroxychloroquine (HCQ) study shows increased mortality in COVID-19 patients just as ICMR widens its use in India
Hydroxychloroquine (HCQ) is an anti-malarial drug which is being tested as a prophylactic treatment to prevent COVID-19 infection worldwide. According to the guidelines laid by the Indian Council of Medical Research (ICMR) on the prophylactic use of hydroxychloroquine on 23rd March 2020, the drug was tested in the laboratories and showed promising results in treating and preventing COVID-19 infection. Since then, many doctors and healthcare workers in India have been given hydroxychloroquine to prevent them from contracting the infection. Moreover, India has also exported the drug to many other countries, including the United States.
However, a recent study published in The Lancet showed that giving hydroxychloroquine to people infected with COVID-19 infection can increase their risk of death. The study was conducted on a massive scale and showed negative effects of hydroxychloroquine and chloroquine on COVID-19 infected people.
Continued use of hydroxychloroquine: ICMR’s revised guidelines for hydroxychloroquine
The ICMR laid down their revised guidelines for hydroxychloroquine on 22nd May 2020, which stated that the medication would also be given to all the healthcare workers working during this pandemic and the frontline workers (including police officers) who are deployed in the containment zones. This decision was based on three studies: a retrospective case-control analysis by ICMR, another conducted by three government hospitals and a third conducted on AIIMS healthcare workers.
The contradictory Lancet study
The study published in The Lancet was based on testing the effect of hydroxychloroquine and chloroquine on COVID-19 patients. The study was conducted by Dr Mandeep Mehra, a Harvard Medical School professor and physician at Brigham and Women’s Hospital, along with his colleagues from other institutions. It was done on 96,032 patients who had been infected with COVID-19 and were hospitalized between 20th December 2019 to 14th April 2020. Out of these people, 14,888 were given the medication while the rest were given a placebo.
The treatment group was divided into four categories depending upon people who received: only chloroquine, chloroquine with antibiotics, only hydroxychloroquine and hydroxychloroquine with antibiotics.
Conclusion of the study
During the study period, 10,698 deaths were reported. The death rate was reported to be 9.3% in the people who got a placebo. However, it was found to be increased in people who got the medication. The study showed that the death rate was 18% in people who got hydroxychloroquine, 23.8% in the ones who got hydroxychloroquine with antibiotics, 16.4% in the group who got chloroquine and 22.2% in those who got chloroquine with the antibiotic.
The study further found that the group who got the drug showed an increased risk of getting irregular heartbeats (arrhythmias). When compared to the group that got a placebo, 6.1% increased risk of arrhythmias were seen in hydroxychloroquine, 8.1% in hydroxychloroquine with the antibiotic, 4.3% in chloroquine and 6.5% chloroquine with the antibiotic.
To conclude, the study suggests that HCQ should not be used against COVID-19 outside of clinical trials at this point.
For more information, read our article on Is Hydroxychloroquine really effective against COVID-19?.
Health articles in Firstpost are written by myUpchar.com, India’s first and biggest resource for verified medical information. At myUpchar, researchers and journalists work with doctors to bring you information on all things health.
Updated Date: May 25, 2020 16:44:09 IST
Tags : Antibiotics, Arrythmias, Chloroquine, Coronavirus, Coronavirus Outbreak, COVID-19, covid19, HCQ, Health India Positive, Hydroxychloroquine, Hydroxychloroquine Coronavirus, Malaria, Myupchar, NewsTracker
The information provided here is intended to provide free education about certain medical conditions and certain possible treatment. It is not a substitute for examination, diagnosis, treatment, and medical care provided by a licensed and qualified health professional. If you believe you, your child or someone you know suffers from the conditions described herein, please see your health care provider immediately. Do not attempt to treat yourself, your child, or anyone else without proper medical supervision. You acknowledge and agree that neither myUpchar nor firstpost is liable for any loss or damage which may be incurred by you as a result of the information provided here, or as a result of any reliance placed by you on the completeness, accuracy or existence of any information provided herein.
Why social distancing is still the most effective non-pharmaceutical intervention for COVID-19
Studies suggest even mild symptoms of COVID-19 can cause severe damage to lungs, heart and brain
COVID-19 Treatment: Bemcentinib, Heparin and 3 other drugs to be tested by UK in their ACCORD programme
Hydroxychloroquine sustained dose and PPE can reduce COVID-19 risk in healthcare workers, ICMR study says
COVID-19 Testing: Gold nanoparticle-based test kit can give results within 10 minutes
New French study suggests 10% of diabetes patients who contract COVID-19 die within a week
Coronavirus Outbreak Updates: 2,091 people test positive for COVID-19 in Maharashtra today; confirmed cases rise to 54,758 in state
Coronavirus Outbreak Updates: 459 people test positive for COVID-19 in Pune today, total number of cases rises to 6,153
Coronavirus Outbreak Updates: Gujarat BJP MLA Balram Thawani tests positive for COVID-19; 423 new cases reported in state today
Coronavirus Outbreak Updates: Mumbai reports 1,382 new COVID-19 cases; confirmed infections rise to 25,317
Coronavirus Outbreak Updates: Junior assistant in Delhi LG's office tests positive for COVID-19; samples from 40 staff members taken
Coronavirus Outbreak Updates: Film producers' association writes to Uddhav Thackeray requesting resumption of film and TV shoots